Bipolar Depression Before and After Lamotrigine Treatment
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study compared glutamate and other neurometabolites measured by proton magnetic
resonance spectroscopy (1H-MRS) in bipolar I and II patients currently depressed with
age-matched healthy controls. The study will also compare 1H-MRS of bipolar I and II patients
before and after taking a 12-week course of lamotrigine.
The goal of this study was to better understand the neurobiology of bipolar depression and
how lamotrigine may therapeutically impact brain function and mood response.
The hypothesis was that in comparison to non-remission participants, bipolar participants who
achieve remission (defined as a Montgomery Asberg Depression Rating Scale (MADRS) score <12
at week 12) associated with lamotrigine monotherapy will exhibit a greater decrease in
glutamate (Glu) and an increase in N-acetyl aspartate (NAA), reported as a cerebrospinal
fluid (CSF)-corrected absolute concentration percent change from baseline to endpoint in
anterior cingulate (AC) and dorsolateral prefrontal cortex (DLPFC).